Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 5/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23560471 | 0.98 | FAAH (0.51) | GNAI3GNAO1GNAI1MEN1HTT | |
| SCHEMBL26224205 | 0.93 | FAAH (0.52) | GNAI3GNAO1GNAI1MEN1HTT | |
| SCHEMBL18513691 | 0.86 | FAAH (0.48) | GNAI3GNAO1GNAI1MEN1KMT2A | |
| SCHEMBL23695831 | 0.84 | FAAH (0.50) | MEN1KMT2AFAAHTP53ITGB3 | |
| SCHEMBL23945736 | 0.83 | GNAI3 (0.45) | GNAI3GNAO1GNAI1MEN1HTT | |
| SCHEMBL25654325 | 0.83 | GNAI3 (0.45) | GNAI3GNAO1GNAI1MEN1HTT | |
| SCHEMBL26427815 | 0.82 | GNAI3 (0.47) | GNAI3GNAO1GNAI1MEN1HTT | |
| SCHEMBL25500916 | 0.82 | GNAI3 (0.50) | GNAI3GNAO1GNAI1MEN1HTT | |
| SCHEMBL26228559 | 0.82 | GNAI3 (0.44) | GNAI3GNAO1GNAI1MEN1HTT | |
| SCHEMBL22562145 | 0.81 | GNAI3 (0.55) | GNAI3GNAO1GNAI1MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | GNAI3 1348/4885GNAO1 2450/4885GNAI1 922/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GNAI3 1664/4885GNAO1 2977/4885GNAI1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.